Antibody

Catalog #: APRab06251



Summary

PTEN (Acetyl Lys402) Rabbit Polyclonal Antibody **Production Name**

Description Rabbit Polyclonal Antibody

Rabbit Host **Application** WB.ELISA

Reactivity Human, Mouse, Rat

Performance

Conjugation Unconjugated Modification Acetyl Antibody

Isotype IgG

Clonality Polyclonal **Form** Liquid

Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw Storage

cycles.

Buffer Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% New type preservative N.

Purification Affinity purification

Immunogen

Gene Name **PTEN**

PTEN; MMAC1; TEP1; Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and

Alternative Names dual-specificity protein phosphatase PTEN; Mutated in multiple advanced cancers 1;

Phosphatase and tensin homolog

Gene ID 5728.0

P60484.Synthesized acetyl-peptide derived from the human PTEN around the SwissProt ID

acetylation site of K402.

Application

Dilution Ratio WB 1:500-2000 ELISA 2000-20000

Molecular Weight 47kD

Web: https://www.enkilife.com E-mail: order@enkilife.com techsupport@enkilife.com Tel: 0086-27-87002838

Catalog #: APRab06251



Background

This gene was identified as a tumor suppressor that is mutated in a large number of cancers at high frequency. The protein encoded by this gene is a phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase. It contains a tensin like domain as well as a catalytic domain similar to that of the dual specificity protein tyrosine phosphatases. Unlike most of the protein tyrosine phosphatases, this protein preferentially dephosphorylates phosphoinositide substrates. It negatively regulates intracellular levels of phosphatidylinositol-3,4,5-trisphosphate in cells and functions as a tumor suppressor by negatively regulating AKT/PKB signaling pathway. The use of a non-canonical (CUG) upstream initiation site produces a longer isoform that initiates translation with a leucine, and is thought to be preferentially associated with the mitochondrial inner membrane. This longer isoform may help regulate enercatalytic activity: A phosphoprotein + H(2)O = a protein + phosphate.,catalytic activity:Phosphatidylinositol 3,4,5-trisphosphate + H(2)O = phosphatidylinositol 4,5-bisphosphate + phosphate.,catalytic activity:Protein tyrosine phosphate + H(2)O = protein tyrosine + phosphate.,cofactor:Magnesium.,disease:A microdeletion of chromosome 10q23 involving PTEN and BMPR1A is a cause of chromosome 10g23 deletion syndrome [MIM:612242]. This syndrome shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome, disease:Defects in PTEN are a cause of Bannayan-Zonana syndrome (BZS) [MIM:153480]; also known as Ruvalcaba-Riley-Smith or Bannayan-Riley-Ruvalcaba syndrome (BRRS). In BZS there seems not to be an increased risk of malignancy. It has a partial clinical overlap with CD. BZS is characterized by the classic triad of macrocephaly, lipomatosis and pigmented macules of the gland penis., disease: Defects in PTEN are a cause of Cowden disease (CD) [MIM:158350]; also known as Cowden syndrome (CS). CD is an autosomal dominant cancer predisposition syndrome associated with elevated risk for tumors of the breast, thyroid and skin. The predominant phenotype for CD is multiple hamartoma syndrome, in many organ systems including the breast (70% of CD patients), thyroid (40-60%), skin, CNS (40%), gastrointestinal tract. Affected individuals are at an increased risk of both breast and thyroid cancers. Trichilemmomas (benign tumors of the hair follicle infundibulum), and mucocutaneous papillomatosis (99%) are hallmarks of CD., disease: Defects in PTEN are a cause of macrocephaly/autism syndrome [MIM:605309]. Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD), disease: Defects in PTEN are a cause of oligodendroglioma [MIM:137800]; also called oligodendroblastoma or familial glioma of brain. Oligodendroglioma is a usually benign neoplasm derived from and composed of oligodendrogliocytes in varying stages of differentiation. The majority are seen in adults in the white matter of the brain, disease: Defects in PTEN are a cause of Proteus syndrome [MIM:176920]. Proteus syndrome is a hamartomatous disorder characterized by overgrowth of multiple tissues, connective tissue and epidermal naevi, and vascular malformations. These presentations are usually apparent at birth or soon after and continue to develop as the patient ages. It is named after the Greek god Proteus who, legend has it, could change his shape at will to avoid capture. Tumors, mostly benign but some malignant, have also been reported in Proteus syndrome,

Web: https://www.enkilife.com E-mail: order@enkilife.com techsupport@enkilife.com Tel: 0086-27-87002838

Catalog #: APRab06251



generally presenting by the age of 20 years and including papillary adenocarcinoma of the testis, meningioma, and cystadenoma of the ovaries, disease: Defects in PTEN are a cause of squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]., disease: Defects in PTEN are a cause of susceptibility to endometrial cancer [MIM:608089]., disease: Defects in PTEN are a cause of VACTERL association with hydrocephalus [MIM:276950]; which includes also VATER association with hydrocephalus. VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects, disease: Defects in PTEN are involved in prostate cancer [MIM:176807], disease: Defects in PTEN are the cause of Lhermitte-Duclos disease (LDD) [MIM:158350]; also known as cerebelloparenchymal disorder VI. LDD is characterized by dysplastic gangliocytoma of the cerebellum which often results in cerebellar signs and seizures. LDD and CD seem to be the same entity, and are considered as hamartoma-neoplasia syndromes., disease: Mutations of PTEN are found in a large number of cancers., domain: The C2 domain binds phospholipid membranes in vitro in a Ca(2+)-independent manner; this binding is important for its tumor suppressor function., function: Tumor suppressor. Acts as a dual-specificity protein phosphatase, dephosphorylating tyrosine-, serineand threonine-phosphorylated proteins. Also acts as a lipid phosphatase, removing the phosphate in the D3 position of the inositol ring from phosphatidylinositol 3,4,5-trisphosphate, phosphatidylinositol 3,4-diphosphate, phosphatidylinositol 3phosphate and inositol 1,3,4,5-tetrakisphosphate with order of substrate preference in vitro PtdIns(3,4,5)P3 > PtdIns(3,4)P2 > PtdIns3P > Ins(1,3,4,5)P4. The lipid phosphatase activity is critical for its tumor suppressor function. Antagonizes the PI3K-AKT/PKB signaling pathway by dephosphorylating phosphoinositides and thereby modulating cell cycle progression and cell survival. The unphosphorylated form cooperates with AIP1 to suppress AKT1 activation. Dephosphorylates tyrosine-phosphorylated focal adhesion kinase and inhibits cell migration and integrin-mediated cell spreading and focal adhesion formation. May be a negative regulator of insulin signaling and glucose metabolism in adipose tissue.,induction:Down-regulated by transforming growth factor beta (TGF-beta).,PTM:Phosphorylated in vitro by MAST1, MAST2 and MAST3. Phosphorylation results in an inhibited activity towards PIP3. Phosphorylation can both inhibit or promote PDZ-binding, similarity: Contains 1 C2 tensin-type domain, similarity: Contains 1 phosphatase tensin-type domain, subunit: Monomer. The unphosphorylated form interacts with the second PDZ domain of AIP1 and with DLG1 and MAST2 in vitro. Interacts with MAGI2, MAGI3, MAST1 and MAST3, but neither with MAST4 nor with DLG5. Interaction with MAGI2 increases protein stability., tissue specificity: Expressed at a relatively high level in all adult tissues, including heart, brain, placenta, lung, liver, muscle, kidney and pancreas.,

Research Area

Inositol phosphate metabolism;Phosphatidylinositol signaling system;p53;Focal adhesion;Tight junction;Pathways in cancer;Endometrial cancer; Glioma; Prostate cancer; Melanoma; Small cell lung cancer;


Image Data

Web: https://www.enkilife.com E-mail: order@enkilife.com techsupport@enkilife.com Tel: 0086-27-87002838




Catalog #: APRab06251





Western Blot analysis of HepG2 cells using Acetyl-PTEN (K402) Polyclonal Antibody.. Secondary antibody was diluted at 1:20000



Western Blot analysis of HepG2 cells using Acetyl-PTEN (K402) Polyclonal Antibody. Secondary antibody was diluted at 1:20000

Note

For research use only.